EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model

Hiroaki Iwata iD, Ryuta Saito iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.13288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Hiroaki Iwata und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Japan. Hauptthemen laut MEDLINE: Machine Learning, Drug Discovery, Drug Development. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pharmaceutical industry has increasingly adopted model‐informed drug discovery and development (MID3) to enhance productivity in drug discovery and development. Quantitative systems pharmacology (QSP), which integrates drug action mechanisms and disease complexities to predict clinical endpoints and biomarkers is central to MID3. QSP modeling has proven successful in metabolic and cardiovascular diseases and has expanded into oncology, immunotherapy, and infectious diseases. Despite its benefits, QSP model validation through clinical trial simulations using virtual patients (VPs) is challenging because of parameter variability and high computational costs. To address these challenges, this study proposes a hybrid method that combines Bayesian optimization with machine learning for efficient parameter screening. Our approach achieved an acceptance rate of 27.5% in QSP simulations, which is in sharp contrast with the 2.5% rate of conventional random search methods, indicating more than 10‐fold improvement in efficiency. By facilitating faster and more diverse VPs generation, this method promises to advance clinical trial simulations and accelerate drug development in pharmaceutical research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningDrug DiscoveryDrug DevelopmentBayes TheoremHumansComputer Simulation

Autor:innen und Institutionen

  • Department of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Japan.
  • Discovery Technology Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.

ORCID-Profile: Hiroaki Iwata, Ryuta Saito

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology, Japan
  • Japan Research Foundation for Clinical Pharmacology
  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Iwata, H., & Saito, R. (2025). Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13288

Vancouver

Iwata H, Saito R. Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13288

BibTeX
@article{Iwata2025,
  author = {Iwata, Hiroaki and Saito, Ryuta},
  title = {Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.13288}
}
Kostenlos starten →